Who is sponsoring NCT03590210?

NCT03590210 is sponsored by University Medicine Greifswald.

What drugs are being tested in NCT03590210?

Interventions in NCT03590210: Trabectedin, Nivolumab.

What condition does NCT03590210 study?

NCT03590210 studies Metastatic Adult Soft Tissue Sarcoma.

Is NCT03590210 still recruiting?

NCT03590210 is currently completed. Last updated 8 November 2022.

Last reviewed 2022-11-08 · How we verify

NCT03590210: NiTraSarc

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas

Completed Phase 2 Last updated 8 November 2022

What this trial tests

Phase 2 trial testing Trabectedin in Metastatic Adult Soft Tissue Sarcoma in 92 participants. Completed in 12 February 2022.

Timeline

8 June 2018

Primary endpoint
12 February 2022

12 February 2022

Quick facts

Lead sponsor	University Medicine Greifswald
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	92
Start date	8 June 2018
Primary completion	12 February 2022
Estimated completion	12 February 2022
Sites	9 locations across Germany

Drugs / interventions tested

Trabectedin (TRABECTEDIN) — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Metastatic Adult Soft Tissue Sarcoma — all drugs for Metastatic Adult Soft Tissue Sarcoma →

Sponsor

University Medicine Greifswald

Who can join

18 and older, any sex, with Metastatic Adult Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The "NiTraSarc" trial evaluates the efficacy and feasibility (as determined by the safety and tolerability) of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. · · 2021 · cited 73× · PMID 34925348 · DOI 10.3389/fimmu.2021.775761
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research.
Varayathu H, Sarathy V, Thomas BE, Mufti SS, et al · · 2021 · cited 62× · PMID 34123767 · DOI 10.3389/fonc.2021.559161
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Peranzoni E, Ingangi V, Masetto E, Pinton L, et al · · 2020 · cited 60× · PMID 32793228 · DOI 10.3389/fimmu.2020.01590
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
Martori C, Sanchez-Moral L, Paul T, Pardo JC, et al · · 2022 · cited 43× · PMID 35053602 · DOI 10.3390/cancers14020440
Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.
De Sanctis F, Adamo A, Canè S, Ugel S. · · 2023 · cited 39× · PMID 36161514 · DOI 10.1007/s00281-022-00965-1
Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.
Pillozzi S, Bernini A, Palchetti I, Crociani O, et al · · 2021 · cited 29× · PMID 34207243 · DOI 10.3390/cancers13123044
Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
Yiong CS, Lin TP, Lim VY, Toh TB, et al · · 2023 · cited 26× · PMID 37612756 · DOI 10.1186/s40364-023-00513-5

Verify or expand the search:

Other trials of Trabectedin

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07076186 — Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS · Phase 2 · recruiting
NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W · Phase 2, PHASE3 · active not recruiting
NCT04794127 — Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. · Phase 2 · completed
NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting

Other University Medicine Greifswald trials

Trials by the same sponsor.

NCT06796374 — A Comparison of Fisetin Kinetics in Young and Old Adults · NA · recruiting
NCT06970171 — Acceptance of Mandibular Advancement Devices · NA · not yet recruiting
NCT06939608 — Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions · NA · completed
NCT06273241 — Impact of Food Intake on Berberine Kinetics · NA · completed
NCT06249451 — Staphylococcus Aureus Bacteraemia (SAB)-Support-Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03590210 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medicine Greifswald
Last refreshed: 8 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03590210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing